SRDX NASDAQ

Surmodics, Inc., together with its affiliates, specializes in providing advanced surface modification solutions tailored for intravascular medical devices. Additionally, the company supplies specialized chemical components essential for in vitro diagnostic immunoassay tests and microarrays. Its operations span both the United States and international markets. The company is structured into two primary divisions: Medical Device and In Vitro Diagnostics (IVD). Within the Medical Device segment, Surmodics offers innovative coating technologies that are engineered to improve the accessibility, maneuverability, and reliable deployment of medical devices. This segment also develops drug-delivery coating systems, enabling precise, localized therapeutic release directly from a device's surface for applications in various areas, including coronary, peripheral, neuro-vascular, and structural heart procedures. Moreover, this division is involved in the design, development, and manufacturing of interventional medical instruments, notably balloons and catheters, including drug-coated balloons utilized in the treatment of peripheral arterial disease and other conditions. The IVD segment focuses on creating and producing foundational component products and technologies for diagnostic immunoassay, molecular testing, and biomedical research. Its portfolio in this area includes protein stabilization reagents, specialized substrates, surface coatings, and antigens. Surmodics was established in 1979 and maintains its corporate headquarters in Eden Prairie, Minnesota.